STIMVIA ads

A new chapter begins at STIMVIA! Today marks a defining moment for STIMVIA as we enter our next phase of growth, innovation, and global impact. We are thrilled to welcome Russ Mably as Chief Executive Officer. With more than 25 years of experience building, scaling and leading high-growth medical device and life sciences companies, Russ joins STIMVIA at a pivotal stage in our journey. His track record of commercial execution, strategic leadership and value creation will be instrumental as we accelerate our mission to transform the treatment of bladder dysfunction through breakthrough neuromodulation technology. At the same time, our founder, Lukáš Doskočil, transitions into the role of Founder & Chief Product Officer, where he will continue to lead product innovation, technology development, and the vision that sparked STIMVIA's creation. STIMVIA exists because Lukáš dared to challenge the status quo. His passion, ingenuity and relentless commitment have built the foundation upon which we stand today. We are deeply grateful for his leadership and excited that he will continue to shape the future of our technology and the patients we serve. Together, Russ and Lukáš form a powerful leadership partnership, combining world-class innovation with proven operational and commercial expertise. This combination positions STIMVIA to accelerate clinical adoption, expand strategic partnerships, advance our evidence base and bring life-changing therapies to patients around the world. The opportunity ahead of us has never been greater. To our shareholders, investors, clinical partners and incredible team: thank you for your belief, commitment and support. Everything we have achieved so far has been possible because of you. ⚡ The future of neuromodulation is being built now. ⚡ The future of STIMVIA starts today. Please join us in welcoming Russ to the team! Read our press release in the comments. #STIMVIA #URIS #Neuromodulation #MedTech #MedicalDevices #HealthcareInnovation #Urology #Leadership #Growth #Innovation

Last week, STIMVIA brought clinicians together in Zlín to talk about non-invasive OAB treatment. Our guest speaker, Radek Laža, MD, from Vsetín Hospital shared his clinical experience with OAB treatment, including the strong results his team has achieved using URIS® technology in daily practice. Attendees also had the opportunity to talk to Prof. Jan Krhut, MD, member of our Scientific Advisory Board. Lukáš Peter and Ing.Iveta Koňaříková, Dis., were there for STIMVIA, in conversation with the clinicians in the room. It was also the first event for Radek Vlach, who joined our sales team. Welcome, Radek! As the leader in neurostimulation, STIMVIA designed URIS® to be personalised and precise: therapy settings are tailored to each patient, and the stimulation itself reaches the deep-brain structures involved in bladder control. Thank you to all the physicians who took the time to join us in Zlín for a full room and a great conversation. Lukáš Doskočil #URIS #OAB #Neurostimulation #STIMVIA #Urology #MedTech

#WeAreStimvia Since 2014, we’ve been transforming lives with URIS®, the first technology to non-invasively stimulate deep 🧠 brain structures, offering hope for conditions like OAB. Backed by 100+ international patents and a prestigious TÜV SÜD certification, our innovations are shaping the future of #healthcare. 💜 Want to join us? Follow Stimvia on LinkedIn for open positions!

Millions of people live with a chronic nerve condition and are offered pretty much the same three choices: pills with side effects, clinic visits and injections that pile up over time, or surgery that helps but carries real risk and sometimes needs to be redone. It's no surprise so many give up along the way. That's why we fought to close this gap and created a treatment that actually works, skips the surgery and needles, and can reach patients at scale. We are STIMVIA, and URIS® is our non-invasive, personalised neuromodulation platform - clinically proven in Overactive Bladder, with potential far beyond it. Do you want to learn more? Let's get in touch. #WeAreStimvia #Neuromodulation #OAB #MedTech #Bladder #Urology #URIS

Our mission is to bring URIS® technology to patients in all regions of the Czech Republic. It is now available in 9 offices and hospitals across the Northern Moravia region, and Frýdek-Místek is one of the towns providing our euromodulation therapy for Overactive Bladder (OAB). We’re thrilled to announce that Stimvia’s URIS® is available at Janive Uro Místek! Sincere thanks to Jana Bočková, M.D., Iveta Štrajtová, M.D., and the team for their trust. Unlike other neuromodulation therapies, URIS® combines precision nerve targeting with a biofeedback closed-loop system (BCLS) to ensure optimal stimulation in every session. With our technology, neuromodulation moves to a new era, bringing patients an effective, needle-free, and scientifically validated therapy. And we are so happy to treat patients with a smile. 🙂 Would you like to know more about what we do? Let us know! #STIMVIA #urology #oab #bladder #URIS #noninvasive #neuromodulation Ing.Iveta Koňaříková, Dis. #Neuromodulation #URIS #Stimvia #OveractiveBladder #Urology #Healthcare

Marking the occasion of World Continence Week, Overactive Bladder took centre stage at the Czech Parliament! Yesterday, MP Josef Flek hosted a roundtable at the Chamber of Deputies to discuss how OAB impacts patients' health and social lives. This is a topic we have been living and breathing for years, so it is great to see it getting this level of attention. Alongside presentations from Lukáš Horčička on continence awareness and Prof. Martin Huser on the evolution of OAB treatment, Prof. Jan Krhut presented current treatment options and shared thoughts on a non-invasive, patient-oriented approach. In the Czech Republic alone, OAB affects roughly 1 million people. The state budget spends a staggering 3.2 billion CZK every year just on managing the symptoms of incontinence with hygiene pads. At STIMVIA, we believe that we need a shift in how we fund medical technology to build a truly sustainable healthcare system. Public insurance should adapt to cover modern, non-invasive treatments and therapies that treat the root cause. We are incredibly glad to see this crucial issue finally becoming a matter of public debate. #WeAreStimvia #OAB #Urology #Urogynecology #NonInvasive #MedTech #URIS